COLORADO SPRINGS, Colo.,
March 9, 2015 /PRNewswire/
-- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, is pleased to announce it is set to release its
first line of European products that will feature Cannabis Science
proprietary formulations developed in Spain and the
Netherlands at Spannabis 2015, taking place in Barcelona, Spain from March 20th until the
22nd, the largest
Cannabis conference in the world. Other European markets will
follow as jurisdictional laws permit.
Spannabis is the largest cannabis conference in the world and
has been held in Barcelona since
2004. Cannabis Science is pleased to exhibit for the first time at
the internationally acclaimed conference to showcase its initial
European product line. Dr. Mario
Lap, President of Cannabis Science European Operations will
be present. " We are delighted to be attending Spannabis and
showcasing our products that have been in drug development pipeline
for the last 2 years, after rigorous testing we are excited to show
them to Spain and the rest of the
world."
At the core of the new products are Cannabis Science's
proprietary formulations that have been undergoing development in
Spain and the Netherlands.
Mid-Tier Critical Ailment Application Usage (new
formulations)
1. CS-M4 –
(Ingested and Topical formulations)
Applications: side effects chemo therapy, chronic pain, muscle
problems, sleeping disorders, nausea, ADHD, Rheumatism, arthritis,
infections, diabetes, manic depression and fibromyalgia.
2. CS-M18 –
(Ingested and Topical formulations)
Applications: side effects chemo therapy, chronic pain, muscle
problems, sleeping disorders, nausea, ADHD, Rheumatism, arthritis,
infections, diabetes, manic depression and fibromyalgia.
3. CS-ACCV –
(Topical Formulations)
Applications: rheumatism, fibromyalgia, arthritis, eczema,
sporting injuries, radiotherapy wounds, muscle and neck pain.
4. CS-CLDL –
(Topical Formulations) whole plant based cannabinoid
formulation
Applications: radiotherapy wounds, rheumatism, open wounds,
sensitive and irritated skin.
5. CS-CRRT –
(Topical Formulations) whole plant based cannabinoid
formulation
Applications: various skin complaints, wounds and eczema.
"This will be the first time Cannabis Science has publicly
showcased products to a European audience. We are pushing to get
the product line into the hands of people needing it most," said Mr. Raymond C. Dabney, President & CEO, Cannabis
Science, Inc.
Catalonia has recently passed laws to introduce medical cannabis
clubs in Spain under Spanish
law. Cannabis Science intends on leveraging its experience in
regulatory frameworks to establish and be a driving force in the
cultivation, research and development around extraction and helping
the introduced regulatory measures co-exist within a developing
larger European market.
Cannabis Science is currently harvesting 40 Acres of cultivation
facilities in Spain and is working
aggressively to partner with patient organizations, public
healthcare systems and private companies to expand its on-going commitments in the emerging
market.
About Cannabis Science, Inc. Cannabis Science, Inc.,
takes advantage of its unique understanding of metabolic processes
to provide novel treatment approaches to a number of illnesses for
which current treatments and understanding remain unsatisfactory.
Cannabinoids have an extensive history dating back thousands of
years, and currently, there are a growing number of peer-reviewed
scientific publications that document the underlying biochemical
pathways that cannabinoids modulate. The company works with leading
experts in drug development, medicinal characterization, and
clinical research to develop, produce, and commercialize novel
therapeutic approaches.
Forward-Looking Statements This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing words such as "anticipate," "seek,"
intend," "believe," "estimate," "expect," "project," "plan," or
similar phrases may be deemed "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Some or all of the events or results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development
of cannabis-based drugs. Cannabis Science, Inc., does not undertake
any duty nor does it intend to update the results of these
forward-looking statements.
Media Contact:
VAN STONE PUBLICITY
Carrol Van
Stone
carrol@vanstonepublicity.com
Tel: 304-671-0244
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
info@cannabisscience.com
Tel: 1.888.889.0888
Dr. Mario S. Lap
Director & President of European Operations
info@cannabisscience.com
Tel: 1.888.889.0888
www.cannabisscience.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cannabis-science-set-to-release-its-first-line-of-european-products-at-spannabis-2015-taking-place-in-barcelona-spain-from-march-20th-until-the-22nd-300047267.html
SOURCE Cannabis Science, Inc.